Table 2_Case Report: Treatment of refractory lung disease in systemic juvenile idiopathic

Two pediatric case reports detail the treatment of systemic juvenile idiopathic arthritis-associated lung disease with cyclophosphamide and rituximab combination therapy. The 17.4 KB document, authored by William J. Freeman and last updated in May 2026, describes clinical outcomes including reductions in oxygen requirement and pulmonary arterial pressure. It is shared under a CC-BY-4.0 license on figshare.

Use Cases

• Analyzing treatment efficacy for refractory sJIA-LD based on described clinical improvement metrics.
• Studying the relationship between macrophage activation syndrome and lung disease based on the case descriptions.
• Reviewing therapeutic approaches for pulmonary hypertension in autoimmune disorders based on the reported hemodynamic changes.
• Benchmarking clinical outcomes in rare pediatric conditions based on the detailed patient progress narratives.

Strengths

• Provides specific clinical metrics, such as a reduction in mean pulmonary arterial pressure from 47 to 25 mmHg.
• Includes detailed longitudinal patient data, like daily prednisone requirement decreasing from 1 to <0.2 mg/kg/day.
• Document is openly licensed under CC-BY-4.0, permitting reuse and analysis.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (17.4 KB), representing only two case studies.

Provenance

Source

figshare

Collection Method

Clinical case report documentation.

Time Range

Case report period not specified.

Freshness

Last updated 2026-05-04 04:24:23; freshness should be verified.

Geography

Geographic coverage not specified.